Children's Medical Center, Pediatrics Center of Excellence, Tehran, Iran.
Pediatric Rheumatology Society of Iran, Tehran, Iran.
Pediatr Rheumatol Online J. 2022 Sep 5;20(1):78. doi: 10.1186/s12969-022-00735-1.
A20 haploinsufficiency (HA20) is a newly introduced autosomal dominant autoinflammatory disorder, also known as Behcet's-like disease. Some of the most common symptoms of the disease are recurrent oral, genital, and/or gastrointestinal (GI) ulcers, episodic fever, musculoskeletal symptoms, cutaneous lesions, and recurrent infections. Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening condition of multi-organ failure due to excessive immune activation. HLH has been reported in a few HA20 patients. Herein, we report two children with the primary presentation of HLH, with a mutation in TNFAIP3, in favor of HA20.
Our first patient was a 4-month-old boy who presented with fever, irritability, pallor, and hepatosplenomegaly. Pancytopenia, elevated ferritin, and decreased fibrinogen levels were found in laboratory evaluation. He was diagnosed with HLH and was treated with methylprednisolone and cyclosporine. Two years later, whole exome sequencing (WES) indicated a mutation in TNFAIP3 at NM_001270507: exon3: c.C386T, p.T129M, consistent with A20 haploinsufficiency. Etanercept, a TNF inhibitor, was prescribed, but the parents were reluctant to initiate the therapy. The patient passed away with the clinical picture of cerebral hemorrhage. The second patient was a 3-month-old boy who presented with a fever and hepatosplenomegaly. Laboratory evaluation found pancytopenia, hyperferritinemia, hypoalbuminemia, hypertriglyceridemia, and hypofibrinogenemia. With the establishment of the HLH diagnosis, he was treated with etoposide, dexamethasone, and cyclosporine, and recovered. WES results revealed a heterozygous de novo variant of TNFAIP3 (c. T824C in exon 6, 6q23.3) that leads to a proline to leucine amino acid change (p. L275P). He was treated with etanercept and has been symptom-free afterward.
This report is a hypothesis for developing of the HLH phenotype in the presence of TNFAIP3 mutation. Our results provide a new perspective on the role of TNFAIP3 mutation in HLH phenotypes, but more extensive studies are required to confirm these preliminary results.
A20 杂合性不足(HA20)是一种新引入的常染色体显性自身炎症性疾病,也称为贝切特样疾病。该病的一些最常见症状包括复发性口腔、生殖器和/或胃肠道(GI)溃疡、间歇性发热、肌肉骨骼症状、皮肤损伤和反复感染。噬血细胞性淋巴组织细胞增生症(HLH)是一种由于过度免疫激活导致多器官衰竭的危及生命的疾病。已有报道称少数 HA20 患者存在 HLH。在此,我们报告了两例以 HLH 为主要表现的患儿,其 TNFAIP3 存在突变,有利于 HA20 的诊断。
我们的第一个患者是一名 4 个月大的男婴,表现为发热、烦躁、面色苍白和肝脾肿大。实验室检查发现全血细胞减少、铁蛋白升高和纤维蛋白原降低。他被诊断为 HLH,并接受了甲泼尼龙和环孢素治疗。两年后,全外显子组测序(WES)显示 TNFAIP3 中的一个突变位于 NM_001270507:exon3:c.C386T,p.T129M,与 A20 杂合性不足一致。给予 TNF 抑制剂依那西普治疗,但患儿父母不愿开始治疗。患儿因脑出血临床表现死亡。第二个患者是一名 3 个月大的男婴,表现为发热和肝脾肿大。实验室检查发现全血细胞减少、铁蛋白血症、低白蛋白血症、高甘油三酯血症和低纤维蛋白原血症。HLH 诊断确立后,他接受依托泊苷、地塞米松和环孢素治疗,病情缓解。WES 结果显示 TNFAIP3 存在杂合新生突变(c. T824C 位于 6 号外显子,6q23.3),导致脯氨酸突变为亮氨酸(p. L275P)。他接受了依那西普治疗,此后一直无症状。
本报告提出了在 TNFAIP3 突变存在的情况下 HLH 表型发生的假说。我们的结果为 TNFAIP3 突变在 HLH 表型中的作用提供了新的视角,但需要进一步的广泛研究来证实这些初步结果。